Human Platelet Lysates-based Scaffolds for Interfacial Multi-tissue Repair
RIA – Research and Innovation action
Universidade de Aveiro
Charité – Universitätsmedizin Berlin
INEGI – Instituto de Ciência e Inovação em Engenharia Mecânica e Engenharia Industrial
Kuros Biosciences BV
Eligible Total Cost
InterLynk aims to develop multi-tissue 3D patient-specific scaffolds by providing a portfolio of highly compatible and biofunctional composite inks, biomaterials, and streamlining their co-processing using upgraded AM equipment. A double network photocrosslinkable biomaterial system based on PLMA will be used as base matrix. The PLMA-based hydrogels will be further combined with mechanically reinforcing biomaterials, namely CaPbased bioceramics and PCL-LA polymers, to produce bone-like and fibrous structures, respectively, and will be able to be blended with natural drug carriers. Superior biofunctionality of the InterLynk’ scaffolds will be validated in a highly complex multi-tissue interfacial biosystem, the temporomandibular joint.
These scaffolds are expected to have no counterpart in both fabrication and multi-tissue regeneration, overcoming time-consuming and costly procedures in both dimensions. This will increase current AM (bio)fabrication capabilities and application range, widely extending its use. Their high flexibility and unique performance will considerably reduce immune rejection, risk of contamination and, inherently, rehabilitation time of multi-tissue injuries resulting in increasing wellbeing and healthcare costs reduction.
Interlynk has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 953169